PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28866026-10	2017	Furthermore, bezafibrate treatment significantly suppressed interleukin (IL)-1beta-induced vascular endothelial growth factor (VEGF) production in ARPE-19 cells.	Bezafibrate	13-24	interleukin 1 beta	Homo sapiens	60-82	
12595494-6	2003	Activation of PPARgamma with the agonist prostaglandin J2 (10 micro M) and of PPARalpha with either bezafibrate (100 micro M) or Wy14643 (100 micro M) both increased LXRalpha and ABCA1 gene expression also and enhanced apoA1-mediated cholesterol efflux from lipid-loaded cells, even in the presence of IL-1beta.	Bezafibrate	100-111	interleukin 1 beta	Homo sapiens	302-310	
25134759-9	2015	Expression of IL-1beta mRNA by MNCs was also decreased after 24 hours of treatment with 10 mug/mL of bezafibrate, whereas the IL-1beta level in the culture supernatant was significantly decreased after treatment of MNCs with either 1 or 10 mug/mL of bezafibrate.	Bezafibrate	101-112	interleukin 1 beta	Homo sapiens	14-22	
25134759-9	2015	Expression of IL-1beta mRNA by MNCs was also decreased after 24 hours of treatment with 10 mug/mL of bezafibrate, whereas the IL-1beta level in the culture supernatant was significantly decreased after treatment of MNCs with either 1 or 10 mug/mL of bezafibrate.	Bezafibrate	250-261	interleukin 1 beta	Homo sapiens	14-22	
21119093-5	2011	Bezafibrate treatment normalized monocyte release of MCP-1, interleukin-6, TNF-alpha, and interleukin-1beta and also normalized plasma hsCRP levels in mixed dyslipidemic subjects, whereas in IFG individuals the drug reduced only MCP-1 and interleukin-6 release.	Bezafibrate	0-11	interleukin 1 beta	Homo sapiens	90-107	
20631892-3	2010	Treatment of astrocytes with bezafibrate and fenofibrate (0, 5, and 10 microM) reduced the IFNgamma and IL-1beta-induced cell proliferation in a dose-dependent manner.	Bezafibrate	29-40	interleukin 1 beta	Homo sapiens	104-112